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Abstract
Background: Lung cancer is the most common cause of cancer-related deaths. Tobacco smoke
exposure is the strongest aetiological factor associated with lung cancer. In this study, using serial
analysis of gene expression (SAGE), we comprehensively examined the effect of active smoking by
comparing the transcriptomes of clinical specimens obtained from current, former and never
smokers, and identified genes showing both reversible and irreversible expression changes upon
smoking cessation.
Results: Twenty-four SAGE profiles of the bronchial epithelium of eight current, twelve former
and four never smokers were generated and analyzed. In total, 3,111,471 SAGE tags representing
over 110 thousand potentially unique transcripts were generated, comprising the largest human
SAGE study to date. We identified 1,733 constitutively expressed genes in current, former and
never smoker transcriptomes. We have also identified both reversible and irreversible gene
expression changes upon cessation of smoking; reversible changes were frequently associated with
either xenobiotic metabolism, nucleotide metabolism or mucus secretion. Increased expression of
TFF3, CABYR, and ENTPD8 were found to be reversible upon smoking cessation. Expression of
GSK3B, which regulates COX2 expression, was irreversibly decreased. MUC5AC expression was
only partially reversed. Validation of select genes was performed using quantitative RT-PCR on a
secondary cohort of nine current smokers, seven former smokers and six never smokers.
Conclusion: Expression levels of some of the genes related to tobacco smoking return to levels
similar to never smokers upon cessation of smoking, while expression of others appears to be
permanently altered despite prolonged smoking cessation. These irreversible changes may account
for the persistent lung cancer risk despite smoking cessation.
Background
Lung cancer has the highest mortality rate among all types
of malignancies, accounting for approximately 29% of all
cancer-related deaths in the United States [1]. It has been
estimated that in 2006 alone, the number of new lung
cancer cases will exceed 174,000 and approximately
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163,000 people will die of this disease [1]. Tobacco smok-
ing accounts for 85% of the lung cancers. Former heavy
smokers remain at an elevated risk for developing lung
cancer even years after they stop smoking [2,3]. Fifty per-
cent of newly diagnosed lung cancer patients are former
smokers [4]. It is therefore important to understand the
effects of tobacco smoking on the bronchial epithelium in
both active and former smokers.
Recently, a large-scale microarray study characterized gene
expression differences between current, former, and never
smokers [5], and identified specific genes related to xeno-
biotic functions, anti-oxidation, cell adhesion and elec-
tron transport to be more highly expressed in current
smokers relative to never smokers. Genetic regulators of
inflammation and putative tumor suppressor genes
exhibited decreased expression in current smokers relative
to never smokers. Most significantly, a number of genes
were identified that exhibited irreversible expression
changes upon smoking cessation.
Additional reports have also identified increased expres-
sion of various xenobiotic metabolic enzymes including
members of the cytochrome P450 (CYP) and glutathione
S-transferase (GST) families of proteins in response to cig-
arette smoke exposure [5-10]. CYP enzymes mediate the
conversion of benzo (a) pyrene and other polycyclic aro-
matic hydrocarbons (PAH) to carcinogenic intermediates
that interact with genomic DNA [8], thus contributing to
the formation of DNA adducts in smokers [11-13]. Mem-
bers from both of the CYP and GST gene families have
been implicated as potential susceptibility loci mediated
by the presence of single nucleotide polymorphisms
(SNPs) leading to aberrant expression in response to
smoking [14,15].
Another important process associated with tobacco
smoke exposure is the airway mucosal response. In ani-
mal models, it has been shown that exposure to cigarette
smoke induces goblet cell hyperplasia with accompanied
mucus production [16,17]. Moreover, mucin 5
(MUC5AC), has been shown to be the most highly
expressed mucin in bronchial secretions [18], induced in
response to cigarette smoke through an EGFR-dependent
mechanism [19]. However, beyond this, little is known of
the genes that are associated with airway remodeling as a
result of tobacco smoking.
Serial analysis of gene expression (SAGE) is a quantitative
experimental procedure widely used to determine expres-
sion profiles through the enumeration of short sequence
tags and their relative abundance [20]. Although the con-
struction and sequencing of an individual SAGE library is
expensive and laborious compared to microarray analysis,
SAGE offers the invaluable potential for gene discovery as
the analysis is not limited to genes represented on an
array. Moreover, comparisons between independent
experiments can be performed without sophisticated nor-
malization [21,22].
In this study, we compare the bronchial epithelial tran-
scriptomes of current, former, and never smokers to deter-
mine the effect of active smoking on gene expression
using bronchial brushings from the peripheral sub-seg-
mental airways. Genes whose expression is reversible
upon smoking cessation are expected to differ in abun-
dance between current and former smokers, but are simi-
lar between former and never smokers. Conversely, gene
expression that is irreversible upon smoking cessation will
show similar levels in current and former (ever) smokers
but differ between ever and never smokers. Here, we focus
on identifying both reversible and irreversible gene
expression changes and specifically consider these expres-
sion changes in the context of airway mucosal response,
and susceptibility to cancer development.
Results and Discussion
SAGE library statistics
Twenty-four SAGE libraries were constructed from bron-
chial epithelial specimens acquired from eight current
smokers, twelve former smokers and four never smokers
(Table 1). A former smoker was defined as someone who
had stopped smoking for one year or longer. The smoking
status was verified using exhaled carbon monoxide moni-
toring. Raw SAGE data for these transcriptomes has been
made publicly available at National Center for Biotech-
nology Information (NCBI) Gene Expression Omnibus
(GEO) with series accession number GSE5473. From
these 24 libraries, we have collectively sequenced
3,111,471 SAGE tags, yielding 231,866 unique tags, mak-
ing this the largest human SAGE study reported to date
(Figure 1A). Of the unique tags, nearly half were present
in more than one library at a tag count of one or greater,
and 70% (82,983 tags) of these tags map to a UniGene
cluster. As multiple tags frequently map to the same Uni-
Gene cluster, 25,653 unique UniGene clusters are repre-
sented in our dataset. Significantly, over 27,000 tags did
not map to existing annotated genes, reiterating the con-
tinuing potential of re-mining this large dataset as tag-to-
gene mapping improves with the continuing annotation
of human transcripts.
Analysis of the current, former and never smoker 
transcriptomes
We determined both the number of SAGE tags present in
each of the current, former and never smoker transcrip-
tomes, as well as those tags equally represented among the
three different datasets. The criteria chosen for preferential
expression was a threshold of a raw tag count of ≥ 2 across
all samples in a particular set, but not existing in the otherBMC Genomics 2007, 8:297 http://www.biomedcentral.com/1471-2164/8/297
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sets. Out of 3,033 tags expressed in all current smokers, we
found 227 preferentially expressed tags (Additional file
1). In former smokers, 102 tags were found to be prefer-
entially expressed (out of 2,579 tags) (Additional file 2),
and in never smokers, 2,013 tags were found to be prefer-
entially expressed (out of 5,192) (Additional file 3). It
should be noted that the number of tags preferential to
the never smoker set is substantially higher, most likely
due to the lower sample size of never smokers relative to
the other two groups. However, since we are using never
smokers as a reference, a larger transcriptome will lessen
the likelihood that we would find transcripts that are pref-
erentially expressed in current and former smokers that
were not correct. Looking at those tags which are common
to all three groups, it was found that 1,970 tags (mapping
to 1,733 unique genes) were expressed in all 24 libraries
(Additional file 4). A Venn diagram illustrating the expres-
sion patterns of these three groups is given in Figure 1B.
Genes differentially expressed between current and never 
smokers
We used a Mann Whitney U test to identify tags differen-
tially expressed in the transcriptomes of current and never
smokers. Using cut-off requirements of p ≤ 0.05, and a
fold change of the means ≥ 2, we identified 609 SAGE tags
(mapping to 487 unique genes) to be differentially
expressed between current and never smokers (Additional
file 5).
Supervised clustering and principal component analysis 
(PCA) of current, former and never smokers
Using the 609 tags found to be differentially expressed
between current and never smokers (Additional file 5),
single link hierarchical clustering was performed using the
program Genesis  [23]. We hypothesized that these 609
tags would classify current, former and never smokers.
Indeed, distinct clusters emerged separating groups of cur-
rent and former smokers with one exception of Current4
(Figure 2A). Of note, the former smoker who ceased
smoking for only one year (Former 2) clustered with other
former smokers. Moreover, principal component analysis
(PCA) further validates the distinct groups of current,
former and never smokers (Figure 2B).
Reversible gene expression changes upon cessation of 
smoking
To determine reversibility of smoking-related gene expres-
sion changes, we intersected tags differentially expressed
between current and never smokers against tags showing
significant expression difference between current and
former smokers using similar criteria. By comparing these
two sets, we can deduce which gene expressions are revers-
Table 1: Demographics of subjects in study
Sample Name Gender Age at 
Analysis
Pack-Years Smoking 
Status*
Years of smoking 
cessation (years)
Lung function
 (predicted FEV1 %)
Name from 
previous study**
Current 1 F 63 40 CS N/A 69 BE-13
Current 2 M 56 62 CS N/A 89 BE-7
Current 3 F 63 44 CS N/A 96 BE-12
Current 4 M 68 81 CS N/A 76 BE-1
Current 5 M 64 45 CS N/A 73 BE-2
Current 6 M 66 53 CS N/A 85 -
Current 7 M 52 48.1 CS N/A 63 -
Current 8 F 55 34.4 CS N/A 81 -
Former 1 M 68 33 FS 19 50 BE-3
Former 2 M 69 100 FS 1 21 BE-4A/4B
Former 3 M 68 30 FS 1 30 BE-9
Former 4 M 70 75 FS 17 76 BE-5
Former 5 M 67 55 FS 5 N/A BE-6
Former 6 M 65 82 FS 10 59 BE-10
Former 7 F 56 64 FS 1.5 71 BE-11A
Former 8 F 63 45 FS 4.5 83 BE-14
Former 9 M 72 40 FS 32 87 BE-15
Former 10 F 71 56 FS 16 58 BE-16
Former 11 M 72 63 FS 6 N/A BE-8B
Former 12 M 69 55.3 FS 21 57 -
Never 1 M 58 0 NS N/A 115 -
Never 2 F 56 0 NS N/A 104 -
Never 3 M 53 0 NS N/A N/A -
Never 4 F 81 0 NS N/A N/A -
* CS = Current Smoker, FS = Former Smoker, NS = Never Smoker
**Subset of samples were used in a previous study by Lonergan et al 2006 [55]BMC Genomics 2007, 8:297 http://www.biomedcentral.com/1471-2164/8/297
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ible, i.e., which genes are largely influenced by active
smoking. This analysis yielded 161 tags mapping to 121
unique genes, which were deemed statistically significant,
and representing 26% of the total number of differentially
expressed tags between current and never smokers (Figure
3A, Additional file 6). Further analysis of these 121 differ-
entially expressed genes has identified two main func-
tions: xenobiotic metabolism and nucleotide metabolism
(representing 33% of the reversible gene expression
changes) (Table 2) and airway mucus secretion (repre-
senting 12% of the reversible gene expression changes)
(Table 3). Genes related to oxidative stress were consid-
ered as part of the xenobiotic metabolism/nucleic acid
metabolism category, and those genes previously associ-
ated with xenobiotic metabolism and oxidative stress
through smoke exposure were among those identified
[5,24,25].
For example, ectonucleoside triphosphate diphosphohy-
drolase 8 (ENTPD8), an extracellular nucleic acid meta-
bolic enzyme, is among 18 novel genes (labeled in bold
in Table 2) not previously associated with smoking and
whose expression is increased in response to active smok-
ing. According to enzyme classification, ENTPD8 is
involved in purine and pyrimidine metabolism. Hence,
this gene may potentially play a role in the chemical for-
mation of DNA adducts.
Gene expression related to airway muco-ciliary function is
also elevated in both current versus former smokers and
current versus never smokers (Table 3). For example, tre-
foil factor 3 (TFF3), a structural component of mucus that
is elevated in inflammatory response [26,27], and calcium
binding tyrosine-(Y)  phosphorylation regulated (CABYR),
originally shown to be localized in the principal part of
(A) SAGE library statistics: Summary statistics of the 24 SAGE libraries analyzed in this study Figure 1
(A) SAGE library statistics: Summary statistics of the 24 SAGE libraries analyzed in this study. Mapping information was based 
on the May 10th, 2006 version of SAGEGenie [45]. In total, over 3,000,000 SAGE tags were sequenced, with over 110,000 
unique tags represented upon the exclusion of super singleton tags. (Super singleton tags are tags which have a count of 1 in a 
single library only). Approximately 75 % of these 110,000 unique tags, (potentially representing as many unique transcripts), 
mapped to an annotated UniGene cluster. As multiple SAGE tags frequently map to the same UniGene cluster, we have identi-
fied at a total of 25,653 distinct UniGene clusters within our dataset, approximately 68% of which represent previously charac-
terized genes. Notably, 25% of the unique tags had no mapping, suggesting much information is currently unknown. (B) 
Transcriptome Venn diagram: Venn diagram of the transcriptomes of current, former and never smokers. Reported is the 
number of tags which are expressed in every library group at a raw tag count greater than or equal to 2, representing the tags 
which are constitutively expressed in each set. Nearly 2000 SAGE tags, mapping to over 1700 genes are common to all 24 
SAGE libraries. A lower number of never smokers may have contributed to a higher number of preferentially expressed tran-
scripts in this group.
24 bronchial
epithelial libraries
3,111,471 SAGE
tags sequenced 231, 866 unique
SAGE tags
110,289 tags
excluding singletons
82,983 tags
map to
UniGene clusters
27,306 tags 
with no 
UniGene mapping
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17,363 with
annotation
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annotation
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the human sperm flagellum [28], are both highly
expressed in current smokers relative to former and never
smokers. Though TFF3  was recently shown to be
expressed in response to chronic exposure of nicotine in
intestinal cells [29], this is the first report of this gene
being overexpressed within the bronchial epithelium in
response to active smoking. Based on its assumed role in
sperm motility, CABYR may be involved in ciliary func-
tion associated with muco-ciliary clearance response
within the lung [28]. Interestingly, overexpression of
CABYR variants have been reported in a variety of brain
tumors [30], suggesting a role in carcinogenesis. Previous
observation of increased MUC5AC expression in current
relative to never smokers and increased expression of
microseminoprotein, beta- (MSMB), a gene shown to be
present in mucosal secretions [31], supports the possibil-
ity of induction of airway mucosal response in active
smokers [5,24,25,32].
Irreversible gene expression changes upon cessation of 
smoking
By intersecting genes which are differentially expressed
between current and never smokers with those that are
different between former and never smokers, we can iden-
tify irreversible gene expression changes upon smoking
cessation. This analysis yielded 152 tags (124 unique
genes) meeting the criteria of statistical significance (p ≤
0.05) at a fold change ≥ 2 (Figure 3B, Additional file 7).
Although genes identified by this analysis appear to be
functionally diverse, a small number of genes related to
the cell cycle process and DNA repair have been identified
here. For example, expression of P21/Cdc42/Rac1-activated
kinase 1 (PAK1),  cyclin D1 (CCND1), and cyclin G2
(CCNG2)  all appear to be irreversibly lower in ever
(former and current) smokers relative to never smokers.
This finding is consistent with a previous report of
increased inhibition of cell proliferation through genes
such as CDKN1A in a higher stage (GOLD-2) of chronic
obstructive pulmonary disease (COPD) versus the lowest
stage (GOLD-0) [33].
We also found genes associated with DNA repair to be dif-
ferentially expressed between current and never smokers,
but similar between current and former smokers. APEX
nuclease (multifunctional DNA repair enzyme) 1 (APEX1),
High-mobility group box 1 (HMGB1), REV1-like (REV1L),
and Tumor suppressor candidate 4 (TUSC4) are repair genes
which we have found to be irreversibly under-expressed in
ever smokers. Significantly, APEX1  has been shown to
harbor SNPs associated with lung cancer susceptibility
[34]. Moreover, REV1L is involved with the recruitment of
DNA polymerase eta to assist in DNA replication at
arrested replication forks in areas of DNA lesions such as
those formed by thymine dimmers [35,36]. TUSC4, also
known as NPRL2, has recently been shown to increase
(A) Cluster analysis of current, former and never smokers:  Single link hierarchical clustering using the 609 SAGE tags  comprised in Additional file 5 representing tags differentially  expressed between current and never smokers Figure 2
(A) Cluster analysis of current, former and never smokers: 
Single link hierarchical clustering using the 609 SAGE tags 
comprised in Additional file 5 representing tags differentially 
expressed between current and never smokers. Distance 
measure used was a Euclidean distance. The visualization 
package Genesis [23] was used for clustering. Green rectan-
gles represent samples with lower expression for the particu-
lar gene amongst the samples, and red rectangles represent 
samples where the gene is highly expressed relative to other 
samples. (B) Principal component analysis of current, former 
and never smokers. Expression values used were scaled to 
tags per million (TPM). Each tag was then normalized by 
dividing its value by the maximum value for that tag seen in all 
the libraries. Subsequently, this value was then multiplied by 6 
and then subtracted by 3 to put the values ratios in the range 
of -3 to 3. A co-variance based approach was used and the 
statistics toolbox in MatLab (Mathworks) was used. Current 
smokers are represented in red, former smokers are repre-
sented in blue and never smokers are represented in green.
A
-40 -30 -20 -10 0 10 20 30 40
-40
-30
-20
-10
0
10
Principal Component 1
P
r
i
n
c
i
p
a
l
 
C
o
m
p
o
n
e
n
t
 
2
BBMC Genomics 2007, 8:297 http://www.biomedcentral.com/1471-2164/8/297
Page 6 of 13
(page number not for citation purposes)
sensitivity to cisplatin [37]. Finally, HMGB1 has also been
suggested to be involved with the recruitment of other
repair-related proteins [38].
It should be noted that a significant proportion of former
smokers in our sample set exhibited low FEV1 levels, rais-
ing the possibility that airflow obstruction may be a con-
founding issue in this analysis. To address this, we used
the 20 individuals with available FEV1 data to compare
individuals with moderate or severe COPD (FEV1 < 80%,
n = 12) with those individuals that would be classified
with at most mild COPD (FEV1 ≥ 80%, n = 8) according to
the GOLD staging classification based on FEV1  status
[39,40]. Of the 157 tags differentially expressed between
these two groups, only 6 tags overlap with our list of irre-
versible genes (Additional file 8). This minimal overlap
suggests that the irreversible genes identified are not sig-
nificantly associated with airway obstruction based on
FEV1 status. Nonetheless, airway obstruction should be
considered in the interpretation of differential gene
expression between current and former smokers.
Table 2: Reversible gene expression upon smoking cessation related to xenobiotic metabolism and DNA adduct formation (genes in 
bold have not been previously associated with smoking)
Tag Gene Symbol Gene Name CS Mean* FS Mean* NS Mean* P-Value (CVsF)
GGCCCAGGCC ALDH3A1 Aldehyde dehydrogenase 3 family, memberA1 4355 313 261 0.00002
TTAAAAATTC ADH7 Alcohol dehydrogenase 7 (class IV) 899 145 130 0.00002
AGGTCTGCCA*** AKR1C2 Aldo-keto reductase family 1, member C2 547 116 74 0.00002
AATGCTTTTA CYP1B1 Cytochrome P450, family 1, subfamily B, polypeptide 1 204 13 0 0.00002
TTGGAATCCA STAU2 Staufen, RNA binding protein, homolog 2 (Drosophila) 67 17 23 0.00002
TTATCAAATC NQO1 NAD(P)H dehydrogenase, quinone 1 809 202 149 0.00003
CAAATAAACC PIR Pirin (iron-binding nuclear protein) 260 47 43 0.00003
GGCCCCATTT CBR1 Carbonyl reductase 1 144 31 24 0.00003
TATTTTTGTT TXNRD1 Thioredoxin reductase 1 250 88 78 0.00006
GGTGGTGTCT GPX2 Glutathione peroxidase 2 (gastrointestinal) 384 40 46 0.00011
TATTTTTGAA DRB1 Developmentally regulated RNA-binding protein 1 204 32 22 0.00011
TGGGAGTGGG** NMNAT2 Nicotinamide nucleotide adenylyltransferase 2 175 17 9 0.00011
CAAGACCAGT GSTA2 Glutathione S-transferase A2 1436 485 528 0.00019
GCTTGAATAA AKR1B10 Aldo-keto reductase family 1, member B10 (aldose reductase) 332 10 15 0.0003
GTGCAGGGAG SPDEF SAM pointed domain containing ets transcription factor 239 64 50 0.0003
GGAGGCTTCC MECR Mitochondrial trans-2-enoyl-CoA reductase 85 26 22 0.0003
GTGATGTAAG SRXN1 Sulfiredoxin 1 homolog (S. cerevisiae) 63 14 11 0.0003
TATGCTTTAA NT5DC1 5'-nucleotidase domain containing 1 59 23 24 0.0003
GAACGCCTAA DPYSL2 Dihydropyrimidinase-like 2 1 21 23 0.0004
TTTTCTGAAA TXN Thioredoxin 698 326 212 0.00048
CTTGCATAAG CYP1A1 Cytochrome P450, family 1, subfamily A, polypeptide 1 89 2 0 0.00048
GCAAGAAGAG ALDH3A1 Aldehyde dehydrogenase 3 family, memberA1 77 10 2 0.00048
AGAACAAAAC PRDX1 Peroxiredoxin 1 1043 418 510 0.00071
AAATATTTAA SLC35A3 Solute carrier family 35, member A3 47 14 19 0.00071
CGGCTGAATT PGD Phosphogluconate dehydrogenase 252 104 80 0.00106
CTTATCAGTA BTBD7 BTB (POZ) domain containing 7 94 22 2 0.00106
AAGAGTTTTG AKR1B1 Aldo-keto reductase family 1, member B1 (aldose reductase) 25 5 6 0.00141
GCTGAGATGA** CYP4F11 Cytochrome P450, family 4, subfamily F, polypeptide 11 22 6 2 0.00141
GGCGCCTCCT TALDO1 Transaldolase 1 232 76 94 0.00152
GACACAGCAA ENTPD8 Ectonucleoside triphosphate diphosphohydrolase 8 24 3 2 0.00159
CAGTCTAAAA UCHL1 Ubiquitin carboxyl-terminal esterase L1 (ubiquitin 
thiolesterase)
92 4 0 0.00197
ACATCCTAGG ALDH1A1 Aldehyde dehydrogenase 1 family, member A1 60 28 30 0.00216
TTAGAAGGAA NQO1 NAD(P)H dehydrogenase, quinone 1 41 14 9 0.00216
AGGTCTACCA AKR1C2 Aldo-keto reductase family 1, member C2 270 32 8 0.00292
ATTAGGCCTG TXNRD1 Thioredoxin reductase 1 51 19 17 0.00297
GAGAGCTTTG AKR1C3 Aldo-keto reductase family 1, member C3 149 21 22 0.00298
TACGCTTGGT CYB5R1 Cytochrome b5 reductase 1 68 32 30 0.00298
CACTGCCTTG FTH1 Ferritin, heavy polypeptide 1 59 23 17 0.00298
CTGCTGCACT GSR Glutathione reductase 126 54 50 0.0041
GGCAAAATTA SLC35A3 Solute carrier family 35, member A3 73 32 35 0.0041
ACCTTGGGGT NQO1 NAD(P)H dehydrogenase, quinone 1 73 19 6 0.0041
AATGTTCAGG COQ6 Coenzyme Q6 homolog, monooxygenase (yeast) 29 12 4 0.00708
CACTGACCAG NOD27 Nucleotide-binding oligomerization domains 27 31 10 0 0.00927
CTCGGAGGCC SEPX1 Selenoprotein X, 1 71 32 28 0.00956
CTCCAAAAAA CPSF2 Cleavage and polyadenylation specific factor 2, 100 kDa 118 44 14 0.02013
AATGGAAACT GCLM Glutamate-cysteine ligase, modifier subunit 34 16 9 0.03186
*Mean in tags per million (TPM)
** Changed mapping with TAGMapper [56]
***Tag maps with equal reliability to AKR1C1BMC Genomics 2007, 8:297 http://www.biomedcentral.com/1471-2164/8/297
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A similar approach to that described here was undertaken
by Spira et al. where the expression of 13 genes, including
some putative oncogenes and tumor suppressor genes,
was deemed irreversible upon cessation of smoking. How-
ever, none of these 13 genes overlapped with those iden-
tified in our study. This lack of overlap may reflect the
differing locations from which the bronchial brushings
were obtained as Spira et al [5] sampled from the right
main bronchus whereas we have sampled peripheral sub-
segmental airways.
It is interesting to note that MUC5AC appears in both the
lists of statistically reversible and irreversible gene expres-
sion changes suggesting that expression of this gene exhib-
its distinct states of expression among current, former and
never smokers. Moreover, it should also be noted that
although 311 of the 609 tags were classified as either
reversible or irreversible, the remaining 298 tags did not
meet the statistical criteria for either category.
Validation of select gene expression changes using 
quantitative RT-PCR
In addition to the SAGE analysis, which identified genes
associated with airway mucosal response and xenobiotic/
nucleic acid metabolism as distinguishing features
between current and former smokers, we have performed
quantitative RT-PCR on a secondary cohort of current,
former and never smokers to validate selected genes for
expression changes (Additional file 9). In total, five genes
were selected for validation. From the set of reversible
genes, we have chosen CABYR,  ENTPD8, and TFF3
because their expression has not been associated with
smoking previously. In addition, from the irreversible
genes, we have selected MUC5AC. Using the delta-delta-
Ct method to derive expression values, we then employed
a Mann Whitney U Test to determine significance. The
pattern of reversible over-expression in current smokers
for CABYR, ENTPD8, and TFF3 (Figure 4A) and the irre-
versible over-expression of MUC5AC  (Figure 4B)
observed from the SAGE data, was validated by quantita-
tive RT-PCR (Additional file 10). Raw cycle thresholds for
each gene are available in Additional file 9.
Airway epithelium response genes and their role in 
inflammation and cancer
Although the role of xenobiotic metabolism in smoking-
induced carcinogenesis has been well documented [9,15],
the potential influence mediated by changes in the com-
position of the airway mucosa in the development of lung
cancer, has not been thoroughly investigated. It is possible
that constant dysregulation of expression of genes associ-
ated with mucus secretion (such as TFF3 and MUC5AC)
by smoking could potentially have a direct or indirect role
in smoking-induced carcinogenesis.
Principal component of current, former and never smokers  using (A) the 161 tags deemed reversible upon smoking ces- sation (Additional file 6) and (B) the 152 tags deemed irre- versible upon smoking cessation (Additional file 7) Figure 3
Principal component of current, former and never smokers 
using (A) the 161 tags deemed reversible upon smoking ces-
sation (Additional file 6) and (B) the 152 tags deemed irre-
versible upon smoking cessation (Additional file 7). 
Expression values used were scaled to tags per million 
(TPM). Each tag was then normalized by dividing its value by 
the maximum value for that tag seen in all the libraries. Sub-
sequently, this value was then multiplied by 6 and then sub-
tracted by 3 to put the values in the range of -3 to 3. A co-
variance based approach was used and the statistics toolbox 
in MatLab (Mathworks) was used. Current smokers are rep-
resented in red, former smokers are represented in blue and 
never smokers are represented in green.
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One of the many genes involved in lung cancer develop-
ment is cyclooxygenase 2 (COX2), which plays a multi-fac-
eted role in cellular proliferation, migration and
invasiveness [41]. Notably, secretoglobin, family 1A,
member 1 (SCGB1A1) protein has been shown to inhibit
COX2  at the mRNA level [42,43]. We observed that
SCGB1A1  expression is drastically reduced in current
smokers but is expressed at similar levels in former and
never smokers, and a previous study showed decreased
serum SCGB1A1 level in smokers [44]. It should also be
noted that none of the SAGE sequence tags identified in
the analysis mapping to SCGB1A1 are the most reliable
tag according to SAGE Genie [45]. However, even though
the most reliable tag to this gene, CTTTGAGTCC did not
pass statistically, the trend of reduced expression in cur-
rent smokers relative to former smokers and similar
expression between former and never smokers is consist-
ent with the sequence tags that did appear in the analysis.
Moreover, given that multiple tags have appeared from
our analysis, although not as reliably mapped, we are con-
fident that we are detecting SCGB1A1 mRNA expression.
Interestingly, COX2 mRNA expression was not detected in
the bronchial epithelium of current, former and never
smokers from our SAGE data. A recent report demon-
strated a significant increase in COX2 expression in nor-
mal lung fibroblasts when exposed to cigarette smoke
extracts [46]. It is possible that SCGB1A1 involvement is
in the stroma and not in epithelial cells.
Despite lack of knowledge about CABYR, one of its few
known interactions occurs with GSK3B [30].CABYR is a
substrate of GSK3B [30], and exhibits reversible, increased
expression with active smoking (Figure 4A). Though
GSK3B was not identified as a smoking-related gene in
our primary analysis, investigation of the SAGE data
revealed a trend of similar decreased expression in current
and former smokers relative to never smokers. Moreover,
quantitative RT-PCR using a secondary cohort of samples
validated that GSK3B expression is irreversibly reduced in
ever smokers (Figure 4B). Recently, a published report
using porcine tracheobronchial epithelial cells exposed to
cigarette smoke components in vitro, demonstrated an
inhibition of GSK3B  gene expression [47]. GSK3B  has
been shown to negatively interact with COX2  [48].
Reduced expression of GSK3B may therefore account for
exaggerated inflammatory response despite smoking ces-
sation and may contribute to development of lung cancer.
In this study, we have demonstrated differential expres-
sion of various components of respiratory tract mucus
(including TFF3 and MUC5AC) according to smoking sta-
tus (Table 3). However, our data indicates that MUC5AC
expression is not completely reversible upon smoking ces-
sation and in fact, exhibits three statistically distinct levels
of expression between current, former and never smokers
(Figure 4B). TFF2, a related motogen to TFF3, in conjunc-
tion with epidermal growth factor (EGF), has been shown to
promote airway restitution, (i.e., movement of neighbor-
ing airway epithelial cells in response to injury mimicking
rapid epithelium regeneration), through the activation of
the epidermal growth factor receptor (EGFR) [49], expressed
in the normal bronchial mucosa [50,51]. Other studies
have also demonstrated increased expression of
MUC5AC, along with EGFR  and  v-erb-b2 erythroblastic
leukemia viral oncogene homolog 3 (ERBB3) in active smok-
ers [26,32]. We examined EGFR expression in relation to
smoking and found that there was a modest increase of
approximately 1.5-fold between current and former
smokers in our SAGE data. As enhanced expression of
EGFR is well documented in lung cancer [52,53], these
Table 3: Reversible gene expression upon smoking cessation related to mucus secretion (genes in bold have not been previously 
associated with smoking)
Tag Gene Symbol Gene Name CS Mean* FS Mean* NS Mean* P-Value (CVsF)
GAATGAACTG EDIL3 EGF-like repeats and discoidin I-like domains 3 72 5 8 0.00011
CTCCACCCGA TFF3 Trefoil factor 3 (intestinal) 4974 1978 1722 0.00019
GTGGAGAAGA CLDN10 Claudin 10 89 23 26 0.00019
GGAATTGCCC BPIL1 Bactericidal/permeability-increasing protein-like 1 43 4 4 0.00029
TTGGTTTTTG CXCL6 Chemokine (C-X-C motif) ligand 6 147 414 371 0.0003
CCTATCAGTA MSMB Microseminoprotein, beta- 15881 4405 2948 0.00048
CTTCCTGTGA SBEM Small breast epithelial mucin 154 27 32 0.00071
TGGAAATGTG CBARA1 Calcium binding atopy-related autoantigen 1 49 18 15 0.00141
CAAGCATAAA CABYR Calcium binding tyrosine-(Y)-phosphorylation regulated 63 4 4 0.00241
AGGGAGGCAG SCGB1A1 Secretoglobin, family 1A, member 1 135 473 436 0.0041
TATCACATTC CXCL6 Chemokine (C-X-C motif) ligand 6 10 42 29 0.00573
TTGCACCCTT MSMB Microseminoprotein, beta- 71 16 9 0.00735
AGCTTAATGA** SCGB1A1 Secretoglobin, family 1A, member 1 557 1478 3269 0.00956
GAAAAAATAG SCGB1A1 Secretoglobin, family 1A, member 1 (uteroglobin) 88 288 281 0.0124
GTGGCCACGG S100A9 S100 calcium binding protein A9 (calgranulin B) 26 101 63 0.0124
AAAATGTATT CAV2 Caveolin 2 20 6 4 0.0144
GACAAGGATG CX3CL1 Chemokine (C-X3-C motif) ligand 1 29 63 93 0.01586
*Mean in tags per million (TPM)
** Changed mapping with TAGMapper [56]BMC Genomics 2007, 8:297 http://www.biomedcentral.com/1471-2164/8/297
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SAGE and quantitative PCR (qRT-PCR) analysis of select genes: (A) Genes found to have reversible expression upon smoking  cessation Figure 4
SAGE and quantitative PCR (qRT-PCR) analysis of select genes: (A) Genes found to have reversible expression upon smoking 
cessation. Box plots of SAGE data and histograms for qRT-PCR for CABYR, ENTPD8 and TFF3. Distribution of ratios between 
both current vs. former and current vs. former and never (Additional file IV) were found to be statistically different. (B) Genes 
found to be either partially or fully irreversible. Box plots of SAGE data and histograms for qRT-PCR for MUC5AC and GSK3B. 
Distribution of ratios between current vs. former and former vs. never were statistically different for MUC5AC and in addition, 
GSK3B was statistically significant for the combination of current and former vs. never. Box plot analysis was done using the 
Statistics toolbox from the MathWorks MatLab program. Red lines in the boxes represent the median expression value in terms 
of tags per million (TPM), and red "plus" signs represent outliers (values which are greater than 1.5 times the maximum value). 
The bottom and top part of the boxes represent the 2nd and 3rd quartiles of the data respectively. The error bars represent the 
5th and 95th percentiles of the data. Quantitative RT-PCR validation was performed on a second cohort of nine current smok-
ers, seven former smokers and six never smokers. Plotted is the average expression ratio relative to the average expression in 
never smokers of current (red), former (blue) and never (green) smokers. Statistical significance was determined using a one-
tailed p-value from the Mann Whitney U Test (Supplemental Table IX).
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results imply that enhanced expression of TFF3 (and per-
haps other genes associated with airway epithelial
response and mucus secretion) may promote airway resti-
tution in response to active smoking and that constant
induction of airway reconstruction may play a role in the
development of lung cancer (Figure 5).
Conclusion
This study represents the largest human SAGE study
reported to date. Over three million SAGE tags were
sequenced, representing over 110 thousand potentially
unique transcripts expressed within the bronchial epithe-
lium relative to cigarette smoke exposure. These libraries
provide a valuable resource for future data mining. Based
on the gene expression profiles of 24 current, former and
never smokers, we identified both reversible and irrevers-
ible gene expression changes upon smoking cessation.
Specifically, amongst those genes reversibly expressed,
three main functions were identified: xenobiotic metabo-
lism, nucleotide metabolism, and mucus secretion. In
addition, some of the genes associated with airway
mucosal response are strongly involved with airway epi-
thelium repair and regeneration. Interestingly, investigat-
ing airway repair and regeneration revealed genes varying
in the degree of reversibility, including those completely
reversible (TFF3, CABYR), partially reversible (MUC5AC)
and irreversible (GSK3B) expression changes upon smok-
ing cessation. We have validated the SAGE expression data
for TFF3, CABYR, MUC5AC, GSK3B and ENTPD8 using a
secondary cohort of current, former and never smokers.
This is the first study demonstrating smoking-induced
expression changes for this particular set of genes and
importantly, it is the first time partial reversibility
(MUC5AC) and irreversibility (GSK3B) and has been
demonstrated using two different cohorts of samples with
two independent assays for expression quantification. By
comprehensively identifying gene expression changes that
are reversible upon smoking cessation, we have intro-
duced genes which may in future studies be investigated
for polymorphisms, as those genes which are not suffi-
ciently induced in response to smoking may identify can-
didate loci of susceptibility. Similarly, those genes and
functions which do not revert to normal levels upon
smoking cessation may also provide insight into why
former smokers still maintain a risk of developing lung
cancer.
Methods
Specimen collection
Bronchial epithelial cells were collected by bronchial
brushings from 24 subjects – 9 current smokers, 11 former
smokers and 4 never smokers summarized in Table 1 – by
bronchial brushing as described previously [54,55]. The
subjects were volunteer smokers recruited from the com-
munity as part of a NCI-sponsored chemoprevention trial.
The inclusion criteria were: age > 45 years of age and a
smoking history of ≥ 30 pack years. A former smoker was
defined as one who had stopped smoking for at least one
year or more. None of the subjects were on bronchodila-
tor or inhaled steroids. The samples were obtained prior
to treatment with an investigational chemoprevention
agent.
Brushings were obtained from the peripheral airways
using a 1.8 mm brush. A table of the basic demographics
of the subjects used is listed in Table 1.
Construction of SAGE libraries
To deduce the gene expression profiles, we used a method
called serial analysis of gene expression (SAGE) which
quantifies gene expression by the enumeration of tran-
script derived sequence tags [20]. SAGE libraries were con-
structed from each sample using the MicroSAGE protocol
[55], and sequenced to a depth of ~150,000 SAGE tags per
Expression trends of specific genes related to muco-ciliary  function and airway restitution as compared with smoking  status and lung cancer: TFF3, CABYR, and MUC5AC are over  expressed in current smokers with lowered expression in  both former and never smokers Figure 5
Expression trends of specific genes related to muco-ciliary 
function and airway restitution as compared with smoking 
status and lung cancer: TFF3, CABYR, and MUC5AC are over 
expressed in current smokers with lowered expression in 
both former and never smokers. Conversely, SCGB1A1 
shows the opposite effect, with lowered expression in cur-
rent smokers as compared to former and never smokers. 
MUC5AC and TFF3 are known to be components of mucus. 
EGFR levels are positively correlated with smoking status, 
with modestly higher levels in current smokers. MUC5AC 
and EGF have been shown to interact with EGFR in the proc-
ess of airway restitution and SCGB1A1 has been shown to 
decrease levels of cyclooxygenase 2 (COX2) in cancer cells. 
Interestingly, within this process alone, we see reversible 
(TFF3, CABYR), partially reversible (MUC5AC) and completely 
irreversible (GSK3B) expression changes upon smoking ces-
sation. Values refer to tag counts as tags-per-million (TPM).
TFF3
CABYR
MUC5AC
EGFR
SCGB1A1
GSK3B
EGF
COX2
Mucosal
Components
Airway 
Repair and
Regeneration
phosphorylates
X
X
Gene (SAGE Tag)  CSMean  FSMean  NSMean 
MUC5AC (GTGATCAGCT)  3609 1526  448 
TFF3 (CTCCACCCGA)  4974 1978 1722 
SCGB1A1 (CTTTGAGTCC)  22002  43016  36372  
EGF (GAGGCAGGAG)  0 1 2 
EGFR (AGTACCTTAT)  29 20 22 
CABYR (CAAGCATAAA)  63 4  4 
GSK3B (CAATAAAGGT)  8 16 33 
COX2 (CTGTTCCTTT)  0 3 0 
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library. SAGE libraries were deposited in NCBI GEO with
accession number GSE5473. Reproducibility of SAGE
libraries obtained from the same bronchial brush was
shown by our group previously. The R value between two
libraries from the same lysate was 0.97 [55].
SAGE tag-to-gene mapping
Tag-to-gene mapping was performed using a combination
of the May 10th, 2006 build of SAGEGenie [45]. Tags with
low reliability from SAGEGenie in Table 2 and 3 were also
cross-referenced with TagMapper [56].
Statistical analysis of differentially expressed genes
Stringently, only tags which exhibited a mean tag count of
≥ 20 tags per million (TPM) in at least one of current,
former or never smoker SAGE libraries were used in com-
parative analysis. For each specific comparison, in addi-
tion to the tag count requirement, a minimum fold
change of the means of two was also required. The tag
abundance requirement of a mean tag count of 20 TPM
was used to filter the list of tags prior to statistical compar-
ison to reduce the number of false positives. 8148 tags
meet this criterion. Given the variability in smokers and
limited sample size in this study, a non-parametric Mann
Whitney U Test was used to determine if a given tag (rep-
resenting a gene) was differentially expressed using a p-
value threshold of p ≤ 0.05, unadjusted for multiple com-
parisons.
Validation of SAGE-specific targets using quantitative RT-
PCR
Select targets identified in the SAGE study were validated
using quantitative RT-PCR (qRT-PCR) in a second cohort
of nine current, seven former and six never smokers.
Briefly, 100 ng of RNA was isolated and converted to
cDNA in a 50 μl reaction volume using the High-Capacity
cDNA Archive Kit (cat # 4322171, Applied Biosystems). 1
μl of the resulting cDNA was analysed by qPCR, with spec-
ified Taqman primers and TaqMan Universal PCR Master
Mix (cat # 4326708), using the iCycler iQTM Real-Time
PCR Detection System (Bio-Rad). CABYR,  TFF3,
MUC5AC, GSK3B and Actin Beta were monitored for 40
cycles of PCR and ENTPD8 for 50 cycles. Primers used for
qRT-PCR are listed in Additional file 11.
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